Coronavirus Update: CureVac Joins mRNA Vaccines Competitors, Beijing In Lockdown Again
Plus: Hanmi Investigates Oral COVID-19 Vaccine
CureVac starts mRNA vaccine trial, Interprotein uses AI in drug discovery and South Korea's Chong Kun and Hanmi make clinical progress.
You may also be interested in...
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.
Public Company Edition: iTeos, Annexon, Nurix and Inozyme went public on 23 July and now CureVac has added its name to the IPO queue for what could be a large offering. Also, BioNTech raises $511.5m as COVID-19 vaccine progresses and PTC gets $650m from sale of risdiplam royalties.
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.